TABLE 1.

CMV vaccines currently under development

Vaccine	Developer	Antigena			Reference no.
		gB	Pentamer	pp65
Adenovirus vector	Queensland Institute	X			73
Alphavirus replicons	GSK	X		X	74
Canarypox vector	Sanofi			X	75
Dense bodies	Vaccine Project Management, Serum Institute, India	X	X	X	76
DNA plasmids	Astellas, Inovio	X		X	77, 78
Lentivirus particles	Variations Bio	X		X	79
Live attenuated	Medimmune	X		X	80, 81
Live replication-defective	Merck	X	X	X	82
LCMV vector	Hookipa	X		X	83
mRNA	GSK, Moderna	X		X	84
MVA vector	City of Hope	X	X		85
Peptides	City of Hope, University of Heidelberg			X	86
Soluble pentamer	Humabs, Redbiotech GSK		X		87
Subunit gB	Sanofi, GSK	X			8, 9, 88
VSV vector	Yale	X			89

^aLCMV, lymphocytic choriomeningitis virus; VSV, vesicular stomatitis virus. An “X” indicates that the antigen is included in the vaccine candidate.